<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Science and Innovations in Medicine</journal-id><journal-title-group><journal-title xml:lang="en">Science and Innovations in Medicine</journal-title><trans-title-group xml:lang="ru"><trans-title>Наука и инновации в медицине</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2500-1388</issn><issn publication-format="electronic">2618-754X</issn><publisher><publisher-name xml:lang="en">FSBEI of Higher Education SamSMU of Ministry of Health of the Russian Federation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">110951</article-id><article-id pub-id-type="doi">10.35693/2500-1388-2022-7-4-220-225</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Gerontology and geriatrics</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Геронтология и гериатрия</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Association of drug therapy with falls in elderly and senile patients: Subanalysis of the epidemiological study EVKALIPT</article-title><trans-title-group xml:lang="ru"><trans-title>Связь лекарственной терапии с падениями у лиц пожилого и старческого возраста: субанализ эпидемиологического исследования ЭВКАЛИПТ</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3066-4866</contrib-id><name-alternatives><name xml:lang="en"><surname>Khovasova</surname><given-names>Natalya O.</given-names></name><name xml:lang="ru"><surname>Ховасова</surname><given-names>Наталья Олеговна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD, Associate professor, the Chair of Age-related diseases, senior researcher of the laboratory of the musculoskeletal system diseases</p></bio><bio xml:lang="ru"><p>канд. мед. наук, доцент кафедры болезней старения, старший научный сотрудник лаборатории заболеваний костно-мышечной системы</p></bio><email>natashahov@mail.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6021-7864</contrib-id><name-alternatives><name xml:lang="en"><surname>Vorobyeva</surname><given-names>Natalya M.</given-names></name><name xml:lang="ru"><surname>Воробьева</surname><given-names>Наталья Михайловна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD, Head of the laboratory of cardiovascular aging</p></bio><bio xml:lang="ru"><p>д-р мед. наук, заведующая лабораторией сердечно-сосудистого старения</p></bio><email>vorobyeva_nm@rgnkc.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6253-621X</contrib-id><name-alternatives><name xml:lang="en"><surname>Naumov</surname><given-names>Anton V.</given-names></name><name xml:lang="ru"><surname>Наумов</surname><given-names>Антон Вячеславович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD, Professor, the Chair of Age-related diseases, Head of the laboratory of the musculoskeletal system diseases</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор кафедры болезней старения, заведующий лабораторией заболеваний костно-мышечной системы</p></bio><email>nanton78@gmail.com</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4193-688X</contrib-id><name-alternatives><name xml:lang="en"><surname>Tkacheva</surname><given-names>Olga N.</given-names></name><name xml:lang="ru"><surname>Ткачева</surname><given-names>Ольга Николаевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD, Professor, Head of the Chair of Age-related diseases, Director, Chief geriatrician of the Ministry of Health of the Russian Federation</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор, заведующая кафедрой болезней старения, директор, главный внештатный гериатр Министерства здравоохранения РФ</p></bio><email>rgnkc@rgnkc.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Pirogov Russian National Research Medical University</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Pirogov Russian National Research Medical University – Russian Gerontology Clinical Research Center</institution></aff><aff><institution xml:lang="ru">ОСП «Российский геронтологический научно-клинический центр» ФГАОУ ВО «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2022-12-02" publication-format="electronic"><day>02</day><month>12</month><year>2022</year></pub-date><volume>7</volume><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>220</fpage><lpage>225</lpage><history><date date-type="received" iso-8601-date="2022-09-16"><day>16</day><month>09</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-09-27"><day>27</day><month>09</month><year>2022</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2022, Khovasova N.O., Vorobyeva N.M., Naumov A.V., Tkacheva O.N.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2022, Ховасова Н.О., Воробьева Н.М., Наумов А.В., Ткачева О.Н.</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="en">Khovasova N.O., Vorobyeva N.M., Naumov A.V., Tkacheva O.N.</copyright-holder><copyright-holder xml:lang="ru">Ховасова Н.О., Воробьева Н.М., Наумов А.В., Ткачева О.Н.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://innoscience.ru/2500-1388/article/view/110951">https://innoscience.ru/2500-1388/article/view/110951</self-uri><abstract xml:lang="en"><p><bold>Aim</bold> – to evaluate the structure of drug therapy in patients with falls and to identify the associations of falls with drug administration.</p> <p><bold>Material and methods.</bold> This work is a subanalysis of the epidemiological study EVKALIPT. 4301 patients who had information about presence or absence of falls in the previous year were selected. The patients were divided into 2 groups: 1 group (n = 1307) – having falls, 2 group (n = 2994) – without falls. We studied the complaints and medical history, conducted general examination and analyzed medical documentation to get the information on drug treatment. A regular intake of 5 or more drugs was considered polypharmacy.</p> <p><bold>Results.</bold> All patients had chronic diseases. In patients with falls, most diseases were more common, the Charlson Comorbidity Index was higher (5.53±2.4 versus 4.73±2.03, p&lt;0.001), as well as the proportion of high comorbidity (62.2% versus 47.7%, p&lt;0.001). All study participants took medications, on average 5.4 ± 2.6 drugs. The patients with falls received higher number of drugs (5.73±2.6 versus 5.3±2.5, p&lt;0.001). The frequency of polypharmacy was 64.6% and 56.7% (p&lt;0.001) in groups 1 and 2, respectively. The patients with falls were more likely to take sartans, beta-blockers, diuretics, centrally acting antihypertensives, anticoagulants, nitrates, amiodarone, insulin, NSAIDs, proton pump inhibitors, calcium, vitamin D, anti-osteoporrotic therapy. Administration of a number of drugs was associated with falls (OR 1.18-2.15). For some drugs, a trend in favor of falls was revealed. Only statin therapy was associated with a 24% reduction in the odds of falling. The presence of polypharmacy increased the risk of falls by 1.3 times (OR 1.27, 95% CI 1.10-1.46, p=0.001).</p> <p><bold>Conclusion. </bold>Polypharmacy and drug evaluation are important in assessing the risk of falls. In clinical practice, it is necessary to regularly conduct an audit of medications in elderly patients.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Цель</bold> – оценить структуру лекарственной терапии у пациентов с падениями и выявить ассоциации падений с приемом лекарственных препаратов.</p> <p><bold>Материал и методы.</bold> Данная работа является субанализом эпидемиологического исследования ЭВКАЛИПТ. Для субанализа отобрали пациентов в количестве 4301, у которых была информация о падениях за предшествующий год. В зависимости от факта падения пациенты были разделены на 2 группы: 1 группа (n=1307) – с падениями, 2 группа (n=2994) – без падений. Проводили сбор жалоб, анамнеза, общетерапевтический осмотр, анализ медицинской документации для изучения лекарственной терапии. Полипрагмазией считали регулярный прием 5 и более лекарственных препаратов.</p> <p><bold>Результаты.</bold> Все пациенты имели хронические заболевания. У пациентов с падениями большинство заболеваний встречалось чаще, индекс Чарльсон был выше (5,53±2,4 против 4,73±2,03, р&lt;0,001), как и доля пациентов с высокой коморбидностью (62,2% против 47,7%, р&lt;0,001). Все участники исследования принимали лекарственные препараты, в среднем 5,4±2,6 препарата. Пациенты с падениями получали больше лекарственных препаратов (5,73±2,6 против 5,3±2,5, р&lt;0,001). Частота полипрагмазии составила 64,6% и 56,7% (р&lt;0,001) в 1 и 2 группах соответственно. Пациенты с падениями чаще принимали сартаны, бета-блокаторы, диуретики, антигипертензивные препараты центрального действия, антикоагулянты, нитраты, амиодарон, инсулин, НПВП, ингибиторы протонной помпы, препараты кальция и витамин D, антиостеопоротическую терапию. Прием целого ряда лекарственных препаратов был ассоциирован с падениями (ОШ 1,18–2,15). Для некоторых препаратов была выявлена тенденция в пользу падений. И только терапия статинами была ассоциирована со снижением шансов упасть на 24%. Наличие полипрагмазии повышало риск падений в 1,3 раза (ОШ 1,27, 95% ДИ 1,10–1,46, р=0,001).</p> <p><bold>Заключение.</bold> Полипрагмазия и оценка лекарственных препаратов имеют важное значение в оценке риска падений. В клинической практике у лиц пожилого возраста необходимо регулярно проводить ревизию лекарственных препаратов.</p></trans-abstract><kwd-group xml:lang="en"><kwd>falls</kwd><kwd>drugs</kwd><kwd>polypharmacy</kwd><kwd>comorbidity</kwd><kwd>geriatric syndromes</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>падения</kwd><kwd>лекарственные препараты</kwd><kwd>полипрагмазия</kwd><kwd>коморбидность</kwd><kwd>гериатрические синдромы</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Lavan AH, Gallagher PF, O'Mahony D. Methods to reduce prescribing errors in elderly patients with multimorbidity. Clin Interv Aging. 2016;11:857-66. doi: 10.2147/CIA.S80280</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Dagli RJ, Sharma A. Polypharmacy: a global risk factor for elderly people. J Int Oral Health. 2014;6(6):i-ii.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Jokanovic N, Tan EC, Dooley MJ, et al. Prevalence and factors associated with polypharmacy in long-term care facilities: a systematic review. J Am Med Dir Assoc. 2015;16(6):535.e1-12. doi: 10.1016/j.jamda.2015.03.003</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Charlesworth CJ, Smit E, Lee DS, et al. Polypharmacy Among Adults Aged 65 Years and Older in the United States: 1988-2010. J Gerontol A Biol Sci Med Sci. 2015;70(8):989-95. doi: 10.1093/gerona/glv013</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Morin L, Johnell K, Laroche ML, et al. The epidemiology of polypharmacy in older adults: register-based prospective cohort study. Clin Epidemiol. 2018;10:289-298. doi: 10.2147/CLEP.S153458</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Lapeyre-Mestre M, de Castro AM, Bareille MP, et al. Non-steroidal anti-inflammatory drug-related hepatic damage in France and Spain: analysis from national spontaneous reporting systems. Fundam Clin Pharmacol. 2006;20(4):391-5. doi: 10.1111/j.1472-8206.2006.00416.x</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Gosch M, Jeske M, Kammerlander C, Roth T. Osteoporosis and polypharmacy. Z Gerontol Geriatr. 2012;45(6):450-4. doi: 10.1007/s00391-012-0374-7</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Veronese N, Stubbs B, Noale M, et al. Polypharmacy Is Associated With Higher Frailty Risk in Older People: An 8-Year Longitudinal Cohort Study. J Am Med Dir Assoc. 2017;18(7):624-628. doi: 10.1016/j.jamda.2017.02.009</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Montero-Odasso M, Sarquis-Adamson Y, Song HY, et al. Polypharmacy, Gait Performance, and Falls in Community-Dwelling Older Adults. Results from the Gait and Brain Study. J Am Geriatr Soc. 2019;67(6):1182-1188. doi: 10.1111/jgs.15774</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Rawle MJ, Cooper R, Kuh D, Richards M. Associations Between Polypharmacy and Cognitive and Physical Capability: A British Birth Cohort Study. J Am Geriatr Soc. 2018;66(5):916-923. doi: 10.1111/jgs.15317</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Zia A, Kamaruzzaman SB, Tan MP. Polypharmacy and falls in older people: Balancing evidence-based medicine against falls risk. Postgrad Med. 2015;127(3):330-7. doi: 10.1080/00325481.2014.996112</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Dhalwani NN, Fahami R, Sathanapally H, et al. Association between polypharmacy and falls in older adults: a longitudinal study from England. BMJ Open. 2017;7(10):e016358. doi: 10.1136/bmjopen-2017-016358</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Xue L, Boudreau RM, Donohue JM, et al. Persistent polypharmacy and fall injury risk: the Health, Aging and Body Composition Study. BMC Geriatr. 2021;21(1):710. doi: 10.1186/s12877-021-02695-9</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Masumoto S, Sato M, Maeno T, et al. Potentially inappropriate medications with polypharmacy increase the risk of falls in older Japanese patients: 1-year prospective cohort study. Geriatr Gerontol Int. 2018;18(7):1064-1070. doi: 10.1111/ggi.13307</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Ailabouni N, Mangin D, Nishtala PS. DEFEAT-polypharmacy: deprescribing anticholinergic and sedative medicines feasibility trial in residential aged care facilities. Int J Clin Pharm. 2019;41(1):167-178. doi: 10.1007/s11096-019-00784-9</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Corrao G, Mazzola P, Monzio Compagnoni M, et al. Antihypertensive Medications, Loop Diuretics, and Risk of Hip Fracture in the Elderly: A Population-Based Cohort Study of 81,617 Italian Patients Newly Treated Between 2005 and 2009. Drugs Aging. 2015;32(11):927-36. doi: 10.1007/s40266-015-0306-5</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Lo-Ciganic WH, Floden L, Lee JK, et al. Analgesic use and risk of recurrent falls in participants with or at risk of knee osteoarthritis: data from the Osteoarthritis Initiative. Osteoarthritis Cartilage. 2017;25(9):1390-1398. doi: 10.1016/j.joca.2017.03.017</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Seppala LJ, van de Glind EMM, Daams JG, et al. EUGMS Task and Finish Group on Fall-Risk-Increasing Drugs. Fall-Risk-Increasing Drugs: A Systematic Review and Meta-analysis: III. Others. J Am Med Dir Assoc. 2018;19(4):372.e1-372.e8. doi: 10.1016/j.jamda.2017.12.099</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Woolcott JC, Richardson KJ, Wiens MO, et al. Meta-analysis of the impact of 9 medication classes on falls in elderly persons (Archives of Internal Medicine (2009) 169, 21 (1952–1960)). Arch Intern Med. 2010;170(5):477. doi: 10.1001/archinternmed.2009.510</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Chen Y, Zhu LL, Zhou Q. Effects of drug pharmacokinetic/ pharmacodynamic properties, characteristics of medication use, and relevant pharmacological interventions on fall risk in elderly patients. Ther Clin Risk Manag. 2014;10(1):437-448. doi: 10.2147/TCRM.S63756</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Lim LM, McStea M, Chung WW, et al. Prevalence, risk factors and health outcomes associated with polypharmacy among urban community-dwelling older adults in multiethnic Malaysia. PLoS One. 2017;12(3):1-18. doi: 10.1371/journal.pone.017346</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Turégano Yedro M, Núñez Villén A, Romero Vigara JC, et al. Risk of falls and drug use in patients over 65 years of age. The PYCAF study. Semergen. 2019;45(8):528-534. doi: 10.1016/j.semerg.2019.05.009</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Chitty KM, Evans E, Torr JJ, et al. Central nervous system medication use in older adults with intellectual disability: Results from the successful ageing in intellectual disability study. Aust N Z J Psychiatry. 2016;50(4):352-62. doi: 10.1177/0004867415587951</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Hamza SA, Adly NN, Abdelrahman EE, Fouad IM. The relation between falls and medication use among elderly in assisted living facilities. Pharmacoepidemiol Drug Saf. 2019;28(6):849-856. doi: 10.1002/pds.4775</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Tinetti ME, Han L, Lee DS, et al. Antihypertensive medications and serious fall injuries in a nationally representative sample of older adults. JAMA Intern Med. 2014;174(4):588-95. doi: 10.1001/jamainternmed.2013.14764</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Hegeman J, van den Bemt BJ, Duysens J, van Limbeek J. NSAIDs and the risk of accidental falls in the elderly: a systematic review. Drug Saf. 2009;32(6):489-98. doi: 10.2165/00002018-200932060-00005</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Berlie HD, Garwood CL. Diabetes medications related to an increased risk of falls and fall-related morbidity in the elderly. Ann Pharmacother. 2010;44(4):712-7. doi: 10.1345/aph.1M551</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Ham AC, Swart KM, Enneman AW, et al. Medication-related fall incidents in an older, ambulant population: the B-PROOF study. Drugs Aging. 2014;31(12):917-27. doi: 10.1007/s40266-014-0225-x</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Haerer W, Delbaere K, Bartlett H, et al. Relationships between HMG-CoA reductase inhibitors (statin) use and strength, balance and falls in older people. Intern Med J. 2012;42(12):1329-34. doi: 10.1111/j.1445-5994.2011.02622.x</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Scott D, Blizzard L, Fell J, Jones G. Statin therapy, muscle function and falls risk in community-dwelling older adults. QJM. 2009;102(9):625-33. doi: 10.1093/qjmed/hcp093</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Dobkin BH. Underappreciated statin-induced myopathic weakness causes disability. Neurorehabil Neural Repair. 2005;19(3):259-63. doi: 10.1177/1545968305277167</mixed-citation></ref></ref-list></back></article>
